| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 15.811 | 18.509 | 17.376 | 16.786 | 20.141 | 7.415 | 7.518 | 16.563 | 5.471 | 15.306 |
| Total Income - EUR | 15.811 | 18.509 | 17.376 | 18.288 | 20.141 | 8.660 | 7.518 | 19.112 | 5.471 | 15.514 |
| Total Expenses - EUR | 12.838 | 12.401 | 14.775 | 14.552 | 16.172 | 11.081 | 12.382 | 20.724 | 13.822 | 17.201 |
| Gross Profit/Loss - EUR | 2.973 | 6.108 | 2.602 | 3.736 | 3.968 | -2.421 | -4.864 | -1.612 | -8.351 | -1.688 |
| Net Profit/Loss - EUR | 2.499 | 5.735 | 2.428 | 3.553 | 3.768 | -2.544 | -4.864 | -1.718 | -8.405 | -2.153 |
| Employees | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 |
Check the financial reports for the company - Alotropic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 4.477 | 4.432 | 4.357 | 3.910 | 2.768 | 2.715 | 2.655 | 2.656 | 2.648 | 2.633 |
| Current Assets | 7.311 | 5.014 | 4.055 | 7.774 | 6.950 | 2.307 | 2.427 | 1.640 | 4.060 | 7.521 |
| Inventories | 21 | 5 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 4.917 | 4.278 | 3.916 | 5.359 | 3.635 | 944 | 1.160 | 1.356 | 1.506 | 1.463 |
| Cash | 2.373 | 730 | 95 | 2.416 | 3.315 | 1.363 | 1.267 | 285 | 2.554 | 6.059 |
| Shareholders Funds | 3.602 | 9.068 | 7.530 | 10.706 | 9.210 | 4.315 | -644 | -2.364 | -10.763 | -12.856 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 8.186 | 492 | 975 | 1.065 | 517 | 707 | 4.536 | 6.661 | 17.471 | 23.010 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 1.191 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5590 - 5590" | |||||||||
| CAEN Financial Year |
5590
|
|||||||||
Comments - Alotropic Srl